Content |
History
2025: Medskan bought out Sber's stake in the KDL network of medical laboratories
At the end of October 2025, it became known that Sberbank Investments had left the founders of Medskan Lab LLC (manages the KDL network of laboratories), transferring its share of 39% to the main owner, Medskan. The transaction amount is 4.767 billion rubles.
Sberbank Investments entered the capital of the Medskan Lab network of clinics in the summer of 2023, acquiring a 49 percent stake. Soon after, the size of the asset decreased to 39%: the company returned 10% of the shares to the founder of the Medskan Group of Companies Yevgeny Tugolukov. And in June 2025, Tugolukov announced his intention to transfer the share of the banking player from KDL to the parent company.
The deal to exit Sberbank Investments from Medskan Lab is aimed at completing the acquisition of the KDL network and reducing the debt burden of Medskan Group of Companies before the planned initial public offering (IPO). In an interview with RBC, Tugolukov said that the medical holding is preparing for placement and is forming an offer in the amount of about 10-15% of the additional issue.
 | There is a plan [for the IPO], we are preparing very tightly. The company we are building must be public, "Tugolukov said. |  |
As of October 2025, 65 medical centers of the Medskan Group of Companies operate in 31 regions of Russia, including diagnostic centers, hospitals with a surgical hospital, multidisciplinary and specialized clinics (including oncological), centers for scientific development and research. In turn, the federal network of medical laboratories KDL, specializing exclusively in laboratory diagnostics, is represented by a large number of medical offices in Russia, as well as laboratory complexes in cities such as Moscow, Saratov, Tyumen, Omsk, Novosibirsk, Novokuznetsk, Yekaterinburg, Kazan, Krasnodar, Astrakhan, Rostov-on-Don, Volgograd and Perm.[1]
2023
Return by Sberbank of 10% of Medskan
On August 11, 2023, it became known that Sberbank Investments LLC returned 10% of Medskan Lab to the founder of the company, Medskan JSC. According to the Unified State Register of Legal Entities, after the transaction, Sberbank Investments has 39% of Medskan Lab, and Medskan JSC has 61%.
Sberbank Investments entered the capital of Medskan Lab LLC in June 2023, investing 2.49 billion rubles in the company.
Medskan Lab LLC was established in August 2022 as a holding company, ownership was transferred to it through another company - Diagnostics LLC - two KDL medical laboratories (KDL Test LLC and KDL LLC), the total revenue of which in 2022 amounted to 11.8 billion rubles.
Medskan JSC was established in July 2020 and, as of August 2023, controls about thirty medical specialization companies. At the end of 2022, the owners were Evgeny Tugolukov (74.99%) and Rusatom Healthcare (25.01%), which is part of the Rosatom group of companies. Rusatom Healthcare entered the capital of Medskan JSC in February 2022, having bought an additional issue of 2.49 billion rubles.[2]
Sber received 49% of Medskan lab
The medical holding Medical scan"" sold 49% of Medskan Lab LLC to the company Sberbank investment"." According to "," SPARK-Interfax the deal closed on June 2, 2023.
According to Vedomosti, Medskan Lab is managing laboratory centers based on the holding's multidisciplinary clinics in Moscow, Kursk and Perm. Medskan bought the KDL network from the UFG Private Equit fund, which consisted of 13 laboratories and over 350 medical offices in more than 40 cities of Russia. In 2023, 55 more Novascreen laboratories entered the KDL network, the latter's website said earlier. The structure of this deal is still not clear.
The holding includes 58 medical centers in 20 regions of Russia, which include hospitals with a surgical hospital, multidisciplinary and specialized clinics. Why Sberbank Investments bought a stake in Medskan Lab is not specified by early June 2023. According to one of the consultants with whom Vedomosti talked, bank structures are quite often included in the management company of their borrowers in order to control processes and influence decision-making in companies. However, in such cases, as a rule, acquired shares are limited to 5%.
As noted by RNC Pharma Development Director Nikolai Bespalov and DSM Group CEO Sergei Shulyak, Sberbank Investments could see Medskan Lab as an opportunity for a profitable portfolio investment. Shulyak suggested that Medskan laboratories could in the future enter the Sberbank ecosystem as part of the company's strategy to expand the range of services.
Analysts estimate the purchase amount of 49% of Medskan Lab LLC by Sberbank Investments at about 3 billion rubles and add that the real value of the transaction could be less, since Sberbank acts as its lender.[3]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |